Definitive Therapy for Oligometastatic Solid Malignancies
Public ClinicalTrials.gov record NCT01898962. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective Investigation of Definitive Targeted Therapy for Solid Malignancies With Oligometastases
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Patients with metastatic cancer are usually treated with systemic therapy (treating the entire body) with the assumption that any localized treatment of clinically apparent metastases would not impact survival. In the setting of increasingly effective systemic therapy and limited metastatic disease, aggressive treatment to clinically active sites of disease (alone or in addition to systemic therapy) may improve survival.
Study identification
- NCT ID
- NCT01898962
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 110 participants
Conditions and interventions
Conditions
Interventions
- Complete Surgical Removal Procedure
- Stereotactic Radiosurgery Radiation
- Ablative external beam radiation dose Radiation
- Subtotal surgical removal plus ablative radiation dose Procedure
- Radioembolization Radiation
Procedure · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2005
- Primary completion
- Nov 30, 2018
- Completion
- Nov 30, 2018
- Last update posted
- Jul 14, 2013
2005 – 2018
United States locations
- U.S. sites
- 4
- U.S. states
- 1
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rocky Mountain Cancer Centers - Aurora | Aurora | Colorado | 80012 | Recruiting |
| Rocky Mountain Cancer Centers - Boulder | Boulder | Colorado | 80303 | Recruiting |
| Rocky Mountain Cancer Centers - Littleton | Littleton | Colorado | 80120 | Recruiting |
| Rocky Mountain Cancer Centers - Thornton | Thornton | Colorado | 80260 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01898962, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 14, 2013 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01898962 live on ClinicalTrials.gov.